Gutema Girma, Homa Gadissa
Pharmacology, Rift Valley University, Adama, ETH.
School of Pharmacy, University of Oslo, Oslo, NOR.
Cureus. 2022 Jan 8;14(1):e21035. doi: 10.7759/cureus.21035. eCollection 2022 Jan.
In this study, we aim to synthesize some evidence on the impacts that coronavirus disease 2019 (COVID-19) is having on the epidemiology of antimicrobial resistance (AMR) in Africa since it was declared a global pandemic by the WHO in March 2020. A scoping review was undertaken by collecting and curating relevant resources from peer-reviewed articles and also from the gray literature. Mixed approaches of extracting data (qualitative and quantitative) were employed in synthesizing evidence, as suggested by the Health Evidence Network. A model constructed based on the synthesis of early evidence available on the effects of factors linked to COVID-19 in impacting the evolution of AMR in Africa predicted that, in cumulative terms, those factors favoring the evolution of AMR outpace those disfavoring it by no less than three folds. COVID-19 is likely fueling the evolution of AMR almost unhindered in Africa. Due to the recognition of this crisis, concerted efforts for resource mobilization and global cooperation are needed to tackle it.
在本研究中，我们旨在综合一些证据，以说明自2020年3月世界卫生组织宣布2019冠状病毒病（COVID-19）为全球大流行以来，它对非洲抗菌药物耐药性（AMR）流行病学产生的影响。通过从同行评审文章以及灰色文献中收集和整理相关资源，进行了一项范围综述。按照健康证据网络的建议，在综合证据时采用了混合的数据提取方法（定性和定量）。基于对与COVID-19相关因素影响非洲AMR演变的早期证据的综合构建的一个模型预测，从累积角度来看，那些有利于AMR演变的因素比不利于它的因素至少高出三倍。在非洲，COVID-19可能几乎不受阻碍地推动着AMR的演变。鉴于认识到这一危机，需要齐心协力进行资源调动和全球合作来应对它。
